Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioimmunoradiotherapy (Avelumab, Cetuximab, Radiotherapy) in LA-SCCHN
NCT02938273Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Occurrence of grade 3-5 toxicity at 26 weeks. Started Feb 2017; status: completed.
02
Drugs
avelumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02938273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938273.